← Leaderboards
Lawrence M Pfeffer
University Of Tennessee Health Sci Ctr
$5,400,665
Attributed
$7,430,379
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $768.8K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,430,379 · 4
By mechanism
R01$6,440,648 · 3
U19$989,731 · 1
Top collaborators
- Andrew M Davidoff5 shared
- Duane D Miller3 shared
Most similar at University Of Tennessee Health Sci Ctr
Same institution · by research overlap
- Tony N. Marion$3,429,452
- Jaquelyn F Fleckenstein$1,667,436
- Junming Yue$2,285,470
- Duane D Miller$5,855,110
Others in their field
Top investigators on “Pathway Interactions”
- David Heimbrook · Leidos Biomedical Research, Inc.$202,777,247
- Ralph Parchment · Leidos Biomedical Research, Inc.$146,974,543
- David R. Weir · University Of Michigan At Ann Arbor$129,316,139
- Daniel Ernest Ford · Johns Hopkins University$108,075,637
- David W Simpson · University Of Southern California$88,046,235
- Charles D. Blanke · Oregon Health And Science University$86,571,896
Research focus
Pathway InteractionsInterferonsResponseGene ExpressionNuclearCellsBaseTranscription FactorApoptosisMediatingMolecularChemotherapyCombined Modality TherapyAntiviral AgentsClinical TrialsMalignant NeoplasmsIn VitroGlioblastomaTumorCytokineIn VivoOperative Surgical ProceduresUnited StatesImmune Response
Grant awards (21)
Therapeutic targeting of the SWI/SNF chromatin remodeler to regulate GBM chemosensitivity$512,586
R01 · FY2025 · CA · contact PI
Therapeutic targeting of the SWI/SNF chromatin remodeler to regulate GBM chemosensitivity$482,829
R01 · FY2024 · CA · contact PI
Therapeutic targeting of the SWI/SNF chromatin remodeler to regulate GBM chemosensitivity$504,020
R01 · FY2023 · CA · contact PI
Strategies to improve the antiglioma action of IFN-?: a role for NF-kB inhibition$477,152
R01 · FY2013 · CA · contact PI
Strategies to improve the antiglioma action of IFN-?: a role for NF-kB inhibition$505,966
R01 · FY2012 · CA · contact PI
Strategies to improve the antiglioma action of IFN-?: a role for NF-kB inhibition$510,612
R01 · FY2011 · CA · contact PI
Strategies to improve the antiglioma action of IFN-?: a role for NF-kB inhibition$531,332
R01 · FY2010 · CA · contact PI
Strategies to improve the antiglioma action of IFN-?: a role for NF-kB inhibition$534,932
R01 · FY2009 · CA · contact PI
Interferon System Underlie Differential Response to Therapy for Hepatitis C Virus$233,900
U19 · FY2009 · AI · contact PI
Interferon System Underlie Differential Response to Therapy for Hepatitis C Virus$227,085
U19 · FY2008 · AI · contact PI
IFNAR1 signaling through STAT3, PI-3 kinase and NFkB$287,590
R01 · FY2007 · CA · contact PI
Interferon System Underlie Differential Response to Therapy for Hepatitis C Virus$217,318
U19 · FY2007 · AI · contact PI
IFNAR1 signaling through STAT3, PI-3 kinase and NFkB$296,179
R01 · FY2006 · CA · contact PI
INF System in Differential Response to HCV Therapy$158,515
U19 · FY2006 · AI · contact PI
IFNAR1 signaling through STAT3, PI-3 kinase and NFkB$303,306
R01 · FY2005 · CA
INF System in Differential Response to HCV Therapy$152,913
U19 · FY2005 · AI
IFNAR1 signaling through STAT3, PI-3 kinase and NFkB$303,306
R01 · FY2004 · CA
IFNAR1 signaling through STAT3, PI-3 kinase and NFkB$303,306
R01 · FY2003 · CA
IFNARI SIGNALING THROUGH STAT3, PI 3 KINASE$301,489
R01 · FY2002 · CA
IFNARI SIGNALING THROUGH STAT3, PI 3 KINASE$295,789
R01 · FY2001 · CA
IFNARI SIGNALING THROUGH STAT3, PI 3 KINASE$290,254
R01 · FY2000 · CA